Sandoz announces collaboration agreement with Shanghai Henlius Biotech
The agreement for up to ten biosimilar assets represents one of largest ever biosimilar collaborations for the company
- News
- Research
- Sales
- Regulatory
- Healthcare
- Marketing
Pfizer announces phase 3 results for nonsegmental vitiligo treatment
Litfulo delivered significant, clinically meaningful improvements for both face and body
Lilly to acquire AtaiBeckley in deal worth $2.8bn
The acquisition will advance therapies for treatment-resistant depression and other mental health conditions
FDA grants Fast Track status for peanut allergy immunotherapy
The treatment uses peptides designed to retrain the immune system to tolerate peanuts
Sandoz announces collaboration agreement with Shanghai Henlius Biotech
The agreement for up to ten biosimilar assets represents one of largest ever biosimilar collaborations for the company
CPHI Milan introduces new specialist zones
The event runs from 6-8 October 2026 at the Fiera Milano exhibition centre in Rho, Italy
Latest content
NRG Therapeutics appoints Claus Sundgreen as Chief Medical Officer
Sundgreen previously held senior medical leadership positions across biotechnology and pharmaceutical companies
Read More
Richmond Pharmacology appoints Adam Hurd as Operations Director
Hurd previously spent almost twenty years working within the NHS
Read More
CNX Therapeutics appoints Lucy Ralph as Chief People and Transformation Officer
Ralph previously held senior leadership roles at Norstella and Evaluate
Read More
Healthcare Communications Association appoints Emma Kenny as new interim CEO
Mike Dixon, the current CEO, is retiring after holding the role for nine years
Read More
Intelligence
Forging a connection through creativity
A spark of creativity can cut through complexity, adding real value and helping to forge true connections with patients
Read More
The UK’s life sciences’ crossroads: competing in a market defined by speed, scale and investment
The UK’s challenge is less about capability and more about how well it aligns with the way global pharma now operates
Read More
Launching into an AI-powered future: a prescription for success
Making launch more effective, precise, cost-effective and agile demands new thinking and new technologies
Read More
ASCO 2026: the art of translation
Translating emerging science into care that works meaningfully in practice
Read More
Steering generative AI into the pharma fast lane
Industry needs to press the accelerator to adopt AI across functions to
supercharge launch excellence
Bridging the gap between European brain innovation and real-world policy
Aligning policy and public funding strategies to support brain health across Europe
Read More
Blogs
Latest
Treating phase 2 study design as a scientific decision is compromising launch performance, warns expert
August 17, 2026 | Nmblr|
17th August 2026 – Treating Phase 2 study design solely as a set of scientific decisions, without commercial input, is compromising launch performance, according to …
Genesis Research Group Appoints Sarah Alwardt, PhD, as Executive Vice President, RWE/HEOR
August 11, 2026 | Genesis Research Group|HEOR, Market Access, Pharma, RWE, biotech, genesis, pharmaceutical
Genesis Research Group today announced the appointment of Sarah Alwardt, PhD, as Executive Vice President, RWE/HEOR. She joins the Executive Leadership Team and will lead …
Why Modern Dermatology Demands Curiosity Over Precision
August 5, 2026 | Medscape Education|
In the high-stakes world of healthcare research and product development, success has long been measured by rigid definitions of precision and predictable trajectories. However, as …
Moving Beyond the Pill: Unlocking Value Through Engaged, Empowered, and Educated Patients
July 30, 2026 | Impetus Digital|Health Outcomes, Impetus Digital, Market Access, Medical Innovation, PSP, Pharma Strategy, Value-based care, beyond the pill, digital health, digital voice, health innovation, health literacy, patient activation, patient engagement, patient support program, patientcentricity, real world data, treatment adherence
True “beyond-the-pill” strategy requires shifting from a prescriptive model to a supportive one—using personalized digital tools and authentic patient voices to drive adherence, improve outcomes, …
The Heart of the Matter: Medscape Education’s Cardiology Footprint at ESC 2026
July 28, 2026 | Medscape Education|CME, Cardiology Education, IME, Patient Impact, cardiology
For more than 30 years, Medscape Education has built independent, accredited cardiovascular education designed around one goal: improved patient outcomes. This year at the European …
Permission to pause: making treatment breaks part of the cancer care conversation
August 5, 2026 | Cuttsy + Cuttsy|Cancer, Social Listening, Treatment breaks, Treatment pause, oncology
Exploring how empathetic, patient-centred communication can make planned treatment breaks easier to discuss as part of cancer care.
A seat at the table: what the EU HTA reforms really ask of patient involvement
July 24, 2026 | Cuttsy + Cuttsy|EU HTA, Patient involvement, clinical trials, design
The EU HTA reforms give patients a formal role in assessing new medicines, but meaningful involvement requires more than simply offering them a seat at …
Infographic: Are data blind spots putting your launch at risk?
July 16, 2026 | Inizio|AI, Pharma, Product Launch, healthcare
Commercial pharma launches depend on confident, evidence-led decisions. Yet many launch teams are still working with fragmented data spread across multiple systems, making it difficult …
Why faster trials make participant understanding more important than ever
July 15, 2026 | Cuttsy + Cuttsy|Informed Consent, clinical trials, communication
As clinical trials accelerate, clear, accessible consent is essential to help participants understand, engage with and remain in a study.